Immunologic Research

, Volume 55, Issue 1–3, pp 75–82 | Cite as

Contributions of neutrophils to resolution of mucosal inflammation

  • Sean P. Colgan
  • Stefan F. Ehrentraut
  • Louise E. Glover
  • Douglas J. Kominsky
  • Eric L. Campbell
Immunology in Colorado

Abstract

Neutrophil (PMN) recruitment from the blood stream into surrounding tissues involves a regulated series of events central to acute responses in host defense. Accumulation of PMN within mucosal tissues has historically been considered pathognomonic features of both acute and chronic inflammatory conditions. Historically, PMNs have been deemed necessary but detrimental when recruited, given the potential for tissue damage that results from a variety of mechanisms. Recent work, however, has altered our preconceived notions of PMN contributions to inflammatory processes. In particular, significant evidence implicates a central role for the PMN in triggering inflammatory resolution. Such mechanisms involve both metabolic and biochemical crosstalk pathways during the intimate interactions of PMN with other cell types at inflammatory sites. Here, we highlight several recent examples of how PMN coordinate the resolution of ongoing inflammation, with a particular focus on the gastrointestinal mucosa.

Keywords

Metabolism Hypoxia-inducible factor Inflammation Nucleotide Nucleoside Nucleotidase Mucosa Colitis Neutrophil Epithelium Endothelium Murine model 

References

  1. 1.
    Cohen IK. A brief history of wound healing. Yardley: Oxford Clinical Communications; 1998.Google Scholar
  2. 2.
    Majno G, Joris I. Cells, tissues and disease: principles of general pathology. Cambridge: Blackwell Science; 1996.Google Scholar
  3. 3.
    Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol. 2010;177:1576–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007;21:325–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Laukoetter MG, Bruewer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol. 2006;22:85–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799–809.PubMedCrossRefGoogle Scholar
  8. 8.
    Colgan SP, Eltzschig HK, Eckle T, et al. Physiologic roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2006;2:351–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Khoury J, Ibla JC, Neish AS, et al. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. J Clin Invest. 2007;117:703–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med. 2008;18:103–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med. 2008;85:1295–300.CrossRefGoogle Scholar
  12. 12.
    Bonnans C, Levy BD. Lipid mediators as agonists for the resolution of acute lung inflammation and injury. Am J Respir Cell Mol Biol. 2007;36:201–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Kuhl AA, Kakirman H, Janotta M, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology. 2007;133:1882–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol. 2009;40:519–35. Epub 2008 Oct 31.PubMedCrossRefGoogle Scholar
  15. 15.
    Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med. 2007;85:1295–300.PubMedCrossRefGoogle Scholar
  16. 16.
    Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193:1027–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 2010;7:281–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts in immunity and inflammation. J Immunol. 2010;184:4062–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112:453–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Borregaard N, Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest. 1982;70:550–7.PubMedCrossRefGoogle Scholar
  21. 21.
    El-Benna J, Dang PM, Gougerot-Pocidalo MA. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol. 2008;30:279–89.PubMedCrossRefGoogle Scholar
  22. 22.
    Gabig TG, Bearman SI, Babior BM. Effects of oxygen tension and pH on the respiratory burst of human neutrophils. Blood. 1979;53:1133–9.PubMedGoogle Scholar
  23. 23.
    Semenza GL. Oxygen sensing, homeostasis, and disease. NEJM. 2011;365:537–47.PubMedCrossRefGoogle Scholar
  24. 24.
    Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387–94.PubMedGoogle Scholar
  25. 25.
    Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 (HIF-1) mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993–1002.PubMedGoogle Scholar
  26. 26.
    Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198:783–96.PubMedCrossRefGoogle Scholar
  27. 27.
    Cummins EP, Seeballuck F, Keely SJ, et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology. 2008;134:156–65. Epub 2007 Oct 10.PubMedCrossRefGoogle Scholar
  28. 28.
    Han IO, Kim HS, Kim HC, et al. Synergistic expression of inducible nitric oxide synthase by phorbol ester and interferon-gamma is mediated through NF-kappaB and ERK in microglial cells. J Neurosci Res. 2003;73:659–69.PubMedCrossRefGoogle Scholar
  29. 29.
    Karhausen JO, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098–106.PubMedGoogle Scholar
  30. 30.
    Morote-Garcia JC, Rosenberger P, Nivillac NM, et al. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology. 2009;136:607–18.PubMedCrossRefGoogle Scholar
  31. 31.
    Robinson A, Keely S, Karhausen J, et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008;134:145–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Shah YM, Ito S, Morimura K, et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology. 2008;134:2036–48. 2048 e1-3.PubMedCrossRefGoogle Scholar
  33. 33.
    Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Mariani F, Sena P, Marzona L, et al. Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Lett. 2009;279:221–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Matthijsen RA, Derikx JP, Kuipers D, et al. Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. PLoS ONE. 2009;4:e7045.PubMedCrossRefGoogle Scholar
  36. 36.
    Louis NA, Hamilton KE, Canny G, et al. Selective induction of mucin-3 by hypoxia in intestinal epithelia. J Cell Biochem. 2006;99:1616–27.PubMedCrossRefGoogle Scholar
  37. 37.
    Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648–56.PubMedCrossRefGoogle Scholar
  38. 38.
    Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol. 2005;67:1385–7. Epub 2005 Feb 9.PubMedCrossRefGoogle Scholar
  39. 39.
    Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247–64.PubMedCrossRefGoogle Scholar
  40. 40.
    Kolachala VL, Bajaj R, Chalasani M, et al. Purinergic receptors in gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2008;294:G401–10. Epub 2007 Dec 6.PubMedCrossRefGoogle Scholar
  41. 41.
    Decking UK, Schlieper G, Kroll K, et al. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res. 1997;81:154–64.PubMedCrossRefGoogle Scholar
  42. 42.
    Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol. 2001;41:775–87.PubMedCrossRefGoogle Scholar
  43. 43.
    Aherne CM, Kewley EM, Eltzschig HK. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta 2010.Google Scholar
  44. 44.
    Eckle T, Koeppen M, Eltzschig HK. Role of extracellular adenosine in acute lung injury. Physiology (Bethesda). 2009;24:298–306.CrossRefGoogle Scholar
  45. 45.
    Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology. 2009;111:904–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Chekeni FB, Elliott MR, Sandilos JK, et al. Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis. Nature. 2010;467:863–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Eltzschig HK, Eckle T, Mager A, et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res. 2006;99:1100–8. Epub 2006 Oct 12.PubMedCrossRefGoogle Scholar
  49. 49.
    Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198:783–96.PubMedCrossRefGoogle Scholar
  50. 50.
    Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314:1792–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Linden J. Purinergic chemotaxis. Science. 2006;314:1689–90.PubMedCrossRefGoogle Scholar
  52. 52.
    Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J. 1986;233:309–19.PubMedGoogle Scholar
  53. 53.
    Weissmuller T, Campbell EL, Rosenberger P, et al. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest. 2008;118:3682–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Colgan SP, Eltzschig HK, Eckle T, et al. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2006;2:351–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Madara JL, Patapoff TW, Gillece-Castro B, et al. 5′-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest. 1993;91:2320–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB- alpha ubiquitination. Science. 2000;289:1560–3.PubMedCrossRefGoogle Scholar
  57. 57.
    Cope GA, Deshaies RJ. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell. 2003;114:663–71.PubMedCrossRefGoogle Scholar
  58. 58.
    Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004;5:739–51.PubMedCrossRefGoogle Scholar
  59. 59.
    Parry G, Estelle M. Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Semin Cell Dev Biol. 2004;15:221–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Mendoza HM, Shen LN, Botting C, et al. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J Biol Chem. 2003;278:25637–43. Epub 2003 May 1.PubMedCrossRefGoogle Scholar
  61. 61.
    Wu K, Yamoah K, Dolios G, et al. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J Biol Chem. 2003;278:28882–91. Epub 2003 May 19.PubMedCrossRefGoogle Scholar
  62. 62.
    Kumar A, Wu H, Collier-Hyams LS, et al. The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol. 2009;182:538–46.PubMedGoogle Scholar
  63. 63.
    Banerjee S, Zmijewski JW, Lorne E, et al. Modulation of SCF beta-TrCP-dependent I kappaB alpha ubiquitination by hydrogen peroxide. J Biol Chem. 2010;285:2665–75. Epub 2009 Nov 20.PubMedCrossRefGoogle Scholar
  64. 64.
    Campbell EL, Serhan CN, Colgan SP. Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. J Immunol. 2011;187:3475–81.PubMedCrossRefGoogle Scholar
  65. 65.
    Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J Exp Med. 2009;206:15–23.PubMedCrossRefGoogle Scholar
  66. 66.
    Das UN, Ramos EJ, Meguid MM. Metabolic alterations during inflammation and its modulation by central actions of omega-3 fatty acids. Curr Opin Clin Nutr Metab Care. 2003;6:413–9.PubMedGoogle Scholar
  67. 67.
    Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21:495–505.PubMedGoogle Scholar
  68. 68.
    Calder PC. Fatty acids and gene expression related to inflammation. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;7:19–36. discussion 36–40.PubMedCrossRefGoogle Scholar
  69. 69.
    Belluzzi A. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc. 2002;61:391–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Nakazawa A, Hibi T. Is fish oil (n-3 fatty acids) effective for the maintenance of remission in Crohn’s disease? J Gastroenterol. 2000;35:173–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med. 1996;334:1557–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196:1025–37.PubMedCrossRefGoogle Scholar
  73. 73.
    Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003;278:43807–17.PubMedCrossRefGoogle Scholar
  74. 74.
    Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2- nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192:1197–204.PubMedCrossRefGoogle Scholar
  75. 75.
    Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2:612–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 2002;68–69:433–55.PubMedCrossRefGoogle Scholar
  77. 77.
    Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201:713–22.PubMedCrossRefGoogle Scholar
  78. 78.
    Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178:3912–7.PubMedGoogle Scholar
  79. 79.
    Ariel A, Fredman G, Sun YP, et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol. 2006;7:1209–16.PubMedCrossRefGoogle Scholar
  80. 80.
    Sun YP, Oh SF, Uddin J, et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 2007;282:9323–34.PubMedCrossRefGoogle Scholar
  81. 81.
    Campbell EL, Louis NA, Tomassetti SE, et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 2007;21:3162–70.PubMedCrossRefGoogle Scholar
  82. 82.
    Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461:1287–91.PubMedCrossRefGoogle Scholar
  83. 83.
    Palmer CD, Mancuso CJ, Weiss JP, et al. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol. 2011.Google Scholar
  84. 84.
    Campbell EL, MacManus CF, Kominsky DJ, et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci USA. 2010;107:14298–303.PubMedCrossRefGoogle Scholar
  85. 85.
    Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316:1628–32.PubMedCrossRefGoogle Scholar
  86. 86.
    Moyle PM, Toth I. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008;15:506–16.PubMedCrossRefGoogle Scholar
  87. 87.
    Canny G, Levy O, Furuta GT, et al. Lipid mediator-induced expression of bactericidal/permeability- increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci USA. 2002;99:3902–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Sean P. Colgan
    • 1
  • Stefan F. Ehrentraut
    • 1
  • Louise E. Glover
    • 1
  • Douglas J. Kominsky
    • 1
  • Eric L. Campbell
    • 1
  1. 1.Departments of Medicine and Anesthesiology and the Mucosal Inflammation ProgramUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations